Skip to main content

Table 1 Baseline parameters of 120 patients

From: First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

  All patients (N = 120) HBeAg-positive (n = 67) HBeAg-negative (n = 53)
TDF/TAF (n = 43) ETV (n = 24) p value TDF/TAF (n = 17) ETV (n = 36) p value
Age (years) 42.9 (34.0–55.0) 38.0 (31.0–52.0) 43.8 (38.3–56.0) 0.136 55.0 (41.2–62.1) 40.9 (35.8–50.0) 0.004
Number of male patients 76 (63.3%) 25/43 (58.1%) 16/24 (66.7%) 0.604 11/17 (64.7%) 29/36 (80.6%) 0.002
HBcrAg (log U/mL) 3.64 (2.24–5.23) 5.23 (4.36–5.63) 4.87 (3.40–5.34) 0.066 2.03 (1.35–2.70) 2.25 (1.43–2.99) 0.517
Percentage of patients with undetectable HBcrAg* 0% 0% 0% N/A 0% 0% NA
ALT 73 (53–138) 79 (58–144) 89 (49–304) 0.646 57 (46–79) 72 (54–153) 0.099
Percentage of patients with elevated ALT 103/120 (85.8%) 37/43 (86.0%) 21/24 (87.5%) 1.00 16/17 (94.1%) 29/36 (80.6%) 0.412
Percentage of patients with cirrhosis 7/120 (5.8%) 0/43 (0%) 0/24 (0%) N/A 0/17 (0%) 7/36 (19.4%) 0.082
  1. Continuous variables were expressed as median (interquartile range)ALT: alanine aminotransferase, ETV: entecavir, HBcrAg: hepatitis B core-related antigen, HBeAg: hepatitis B e antigen, TAF: tenofovir alafenamide, TDF: tenofovir disoproxil fumarate
  2. *Undetectable serum HBcrAg is defined as < 0.1 log U/mL